Drug Information
Drug (ID: DG01807) and It's Reported Resistant Information
Name |
N6-Methyladenosine
|
||||
---|---|---|---|---|---|
Synonyms |
N6-Methyladenosine; 1867-73-8; N-Methyladenosine; 6-Methyladenosine; N(6)-Methyladenosine; 6-Methylaminopurinosine; 6-Methylaminopurine riboside; 6-Methylaminopurine D-riboside; 6-Methylaminopurine ribonucleoside; (2R,3S,4R,5R)-2-(Hydroxymethyl)-5-(6-(methylamino)-9H-purin-9-yl)tetrahydrofuran-3,4-diol; N6-methyladenosine (m6A); (N-6)-Methyladenosine; UNII-CLE6G00625; M6A; CHEBI:21891; N(6)-monomethyladenosine; CHEMBL383144; CLE6G00625; NSC-29409; (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(methylamino)purin-9-yl]oxolane-3,4-diol; (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(methylamino)-9H-purin-9-yl]oxolane-3,4-diol; (2R,3S,4R,5R)-2-Hydroxymethyl-5-(6-methylamino-purin-9-yl)-tetrahydro-furan-3,4-diol; NSC627045; 4rdn; 6MD; Prestwick_343; N6 -methyladenosine; Prestwick0_000338; Prestwick1_000338; Prestwick2_000338; Prestwick3_000338; Epitope ID:140951; SCHEMBL40634; BSPBio_000375; MLS002153780; SPBio_002296; BPBio1_000413; DTXSID6020858; HMS1569C17; HMS2096C17; HMS2234N05; HMS3713C17; HY-N0086; ZINC4245632; 2575AH; BDBM50163023; MFCD00005739; PDSP1_001030; PDSP2_001014; s3190; Adenosine, N-methyl- (8CI)(9CI); AKOS024260287; CCG-220338; CS-3285; GS-6701; NCGC00162241-01; NCGC00162241-02; NCGC00162241-04; NCGC00162241-09; SMR001233164; 6-methylamino-9-beta-D-ribofuranosyl-Purine; SW196617-3; 6-methylamino-9-beta-delta-ribofuranosyl-Purine; F12902; Purine, 6-methylamino-9-beta-D-ribofuranosyl-; J-700317; Q6951996; BRD-K81807412-001-03-1; (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-(methylamino)purin-9-yl]tetrahydrofuran-3,4-diol
Click to Show/Hide
|
||||
Structure | |||||
Drug Resistance Disease(s) |
Disease(s) with Clinically Reported Resistance for This Drug
(1 diseases)
Colorectal cancer [ICD-11: 2B91]
[1]
|
||||
Target | . | NOUNIPROTAC | [1] | ||
Click to Show/Hide the Molecular Information and External Link(s) of This Drug | |||||
Formula |
3
|
||||
IsoSMILES |
CNC1=C2C(=NC=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
|
||||
InChI |
InChI=1S/C11H15N5O4/c1-12-9-6-10(14-3-13-9)16(4-15-6)11-8(19)7(18)5(2-17)20-11/h3-5,7-8,11,17-19H,2H2,1H3,(H,12,13,14)/t5-,7-,8-,11-/m1/s1
|
||||
InChIKey |
VQAYFKKCNSOZKM-IOSLPCCCSA-N
|
||||
PubChem CID |
Type(s) of Resistant Mechanism of This Drug
EADR: Epigenetic Alteration of DNA, RNA or Protein
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Colorectal cancer [ICD-11: 2B91]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: Long non-protein coding RNA (RP11-138 J23.1) | [1] | |||
Molecule Alteration | Up-regulation | Expression |
||
Resistant Disease | Colorectal cancer [ICD-11: 2B91.1] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Colorectal cancer tissue | N.A. | ||
In Vivo Model | BALB/c nude mice model | Mus musculus | ||
Experiment for Molecule Alteration |
Microarray assay | |||
Mechanism Description | M6A-induced LncRNA RP11 triggers the dissemination of colorectal cancer cells via upregulation of Zeb1. |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.